Skip to main content

Insmed Incorporated

corporate_fare Company Profile

Insmed Incorporated

INSM·NASDAQ·Life Sciences·CIK 0001104506

INSMED Inc is a global biopharmaceutical company focused on delivering therapies for serious diseases. The company's commercial portfolio and clinical pipeline are structured around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. INSMED also evaluates in-licensing and acquisition opportunities for commercial products, product candidates, and technologies to supplement its internal research and development efforts. The company's two commercial products, ARIKAYCE and BRINSUPRI, are both within the Respiratory therapeutic area. ARIKAYCE (amikacin liposome inhalation suspension) is approved in the US, in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product). In the US, ARIKAYCE received accelerated approval in September 2018 for treating MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. The European Commission (EC) approved ARIKAYCE Liposomal in October 2020 for nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE in March 2021 for NTM lung disease caused by MAC in patients who did not sufficiently respond to prior multidrug treatment. MAC lung disease is a rare, often chronic infection that can cause irreversible lung damage and can be fatal. BRINSUPRI (brensocatib 25 mg and 10 mg tablets) is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older. It was approved in the US in August 2025. In November 2025, the EC approved BRINSUPRI (brensocatib 25 mg tablets) for NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

Insmed Incorporated (NASDAQ:INSM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for INSM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for INSM spans 10-Q, 8-K, 144, DEF 14A.

Recent high-impact activity:

  • Sanofi Weighs Takeover Bid for Insmed, Bloomberg Reports
  • Insmed Lifts 2026 BRINSUPRI Guidance to $1.35–1.40B After $524.4M Q3
  • Insmed Beats Q3 Revenue Estimates and Lifts Full-Year Guidance Range
  • Insmed Q3 Revenue Jumps 268% to $524M as BRINSUPRI Hits $398M in US Sales
  • Insmed Q3 Revenue Hits $524.4M as BRINSUPRI Grows 29% Sequentially, Guidance Raised

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$606.42M
Net Income
-$1.28B
Diluted EPS
-$6.42
Op. Cash Flow
-$935.01M
Free Cash Flow
-$967.58M
Gross Profit
$483.49M
Operating Income
-$1.25B
Cash & Equivalents
$510.44M
Total Debt
$540.96M
Debt / Equity
0.73×
Net Margin
-210.5%
Shares Outstanding
214.26M sh
Source: 10-K · filed 2026-02-19 · accession 0001104506-26-000009

Short Interest & Short Volume

3.56 days to cover

FINRA reported short interest of 14,080,405 shares in INSM as of the October 30, 2026 settlement, a 4.5% increase from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 45.1% of INSM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)14,080,405 shares as of October 30, 2026
Change vs prior period▲ 4.5%
Days to cover3.56 at avg daily volume of 3,955,688
Daily short volume (FINRA facilities)45.1% of 2,654,625 shares on November 20, 2026
5-day average short volume33.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$142.81 +1.05% today
52-week range · as of 2026-10-29 $90.39 – $212.75
Market cap
$31.01B
Volume
6.2M (1.6× avg)
3-mo avg 3.8M
Live data · 2026-11-21 11:04 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed INSM - Latest Insights

INSM
Nov 19, 2026, 10:12 AM EST
Source: Reuters
Importance Score:
9
Price at Filing: $128.03
Real-time Price: $142.81 info
Change: +$14.78 (+12%) info
Market Cap: $31.005B info
INSM
Oct 30, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $110.91
Real-time Price: $142.81 info
Change: +$31.90 (+29%) info
Market Cap: $31.005B info
INSM
Oct 29, 2026, 12:51 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $110.63
Real-time Price: $142.81 info
Change: +$32.18 (+29%) info
Market Cap: $31.005B info
INSM
Oct 29, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $98.77
Real-time Price: $142.81 info
Change: +$44.04 (+45%) info
Market Cap: $31.005B info
INSM
Oct 29, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $98.77
Real-time Price: $142.81 info
Change: +$44.04 (+45%) info
Market Cap: $31.005B info
INSM
Oct 15, 2026, 8:54 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $96.60
Real-time Price: $142.81 info
Change: +$46.21 (+48%) info
Market Cap: $31.005B info
INSM
Oct 05, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Updated Oct 5, 7:43 AM ET — Insmed expects cash flow to turn positive next year.
Price at Filing: $112.63
Real-time Price: $142.81 info
Change: +$30.18 (+27%) info
Market Cap: $31.005B info
INSM
Sep 21, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $125.42
Real-time Price: $142.81 info
Change: +$17.39 (+14%) info
Market Cap: $31.005B info
INSM
Aug 24, 2026, 7:53 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $126.00
Real-time Price: $142.81 info
Change: +$16.81 (+13%) info
Market Cap: $31.005B info
INSM
Aug 06, 2026, 7:21 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $118.00
Real-time Price: $142.81 info
Change: +$24.81 (+21%) info
Market Cap: $31.005B info
INSM
Aug 06, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $121.02
Real-time Price: $142.81 info
Change: +$21.79 (+18%) info
Market Cap: $31.005B info
INSM
Aug 06, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $121.99
Real-time Price: $142.81 info
Change: +$20.82 (+17%) info
Market Cap: $31.005B info
INSM
Jul 16, 2026, 7:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $111.00
Real-time Price: $142.81 info
Change: +$31.81 (+29%) info
Market Cap: $31.005B info
INSM
Jul 16, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $111.00
Real-time Price: $142.81 info
Change: +$31.81 (+29%) info
Market Cap: $31.005B info
INSM
May 15, 2026, 5:05 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $109.14
Real-time Price: $142.81 info
Change: +$33.67 (+31%) info
Market Cap: $31.005B info
INSM
May 07, 2026, 7:53 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $128.36
Real-time Price: $142.81 info
Change: +$14.45 (+11%) info
Market Cap: $31.005B info
INSM
May 07, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $130.00
Real-time Price: $142.81 info
Change: +$12.81 (+10%) info
Market Cap: $31.005B info
INSM
Apr 07, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $163.03
Real-time Price: $142.81 info
Change: -$20.22 (-12%) info
Market Cap: $31.005B info
INSM
Apr 01, 2026, 5:10 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $165.71
Real-time Price: $142.81 info
Change: -$22.90 (-14%) info
Market Cap: $31.005B info
INSM
Apr 01, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $165.71
Real-time Price: $142.81 info
Change: -$22.90 (-14%) info
Market Cap: $31.005B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets